Welcome to EvoCare®-The Care Evolution.

In all sectors of the healthcare market, healthcare providers deliver therapy services, this is the market for the EvoCare Digital Healthcare Platform!

The German market comprises around 3,000 clinics, 90,000 practices and 28,000 care facilities. Every year 9 out of 10 adults use outpatient medical services. To do this, they visit a doctor 9.2 times a year, receiving 300 million prescriptions for remedies with a volume of over €6 billion per year.

Looking for International Investors

Wallstreet Online news item: “Digital health platform helps to expand conventional medical services” Link

INVEST: Bund fördert Investitionen von Business Angels in innovatives EvoCare Digital Healthcare Start-up!

EvoCare offers investors attractive conditions for acquiring shares. BMWi INVEST certifies eligibility for EvoCare! Private investors (business angels) from the EEA receive 20% cash-back, income tax exemptions and exit kickers. The funding is valid until November 25, 2022. Link

EvoCare is offering investors attractive conditions for acquiring shares: The federal government promotes investments in EvoCare. Investors receive 20% cash back, income tax exemptions and exit kicker. The grant is valid until November 25, 2022. INVEST

USP: Recognition as billable, digitized treatment in standard care .

As the healthcare system is a regulated market, all standard care services must be recognized and approved. In Germany health insurers pay €400 billion per year exclusively for approved services. Pilot projects, model trials and studies are not standard care.

The approval of a treatment method requires evidence of effectiveness, economy and necessity (cf. medicine). The audit is carried out by the bodies of the administrations outsourced by the legislature, such as DRV, GBA and others. There are legal procedures! The EvoCare method has been approved by the social security authorities for use in standard care after a 10-year review period by the administrative bodies themselves. This administrative act defines the requirements for future digital methods. According to established law - self-binding of the administration according to Art. 3 GG - every new treatment method must go through the same approval procedure. As such EvoCare has a lead over its competition of 3-5 years. Wirksame Methode

Our goal is to set THE standard for digitized treatments and to expand the partner network internationally. .

Stay up to date.

You can find up-to-date information on: : Twitter + Linkedin

Entries at Healthcare-Startups & gamatik vesta & Bayern International

EvoCare Holding AG at OpenPR

February 10th, 2021

EvoCare receives funding from Startup Shield Bavaria. Link

October 15th, 2020

Digital Health high-flyer: EvoCare is part of the offer of the largest statutory pension insurance in Europe / ensuring patient care in times of the corona pandemic. Link

September 21st, 2020

Press release „Physicians may prescribe EvoCare® - New law governing digital treatments“ Link

September 16th, 2019

Press release: EvoCare Holding AG invests in telemedicine specialist. Innovative telemedicine start-up is growing. Link

August 26th, 2020

The share capital was increased to 1,052,000 euros. Implementation of the decision of March 27, 2019.

February 21st, 2019

Press release: BMWi INVEST: EvoCare Telemedicine is eligible for funding - Federal government supports private investors and business angels. The second grant is valid until February 16, 2020. Link

February 12th, 2019

Workshop for orthopedists at Apo-Bank Munich. "Digitization in Orthopedics" with EvoCare Holding AG. Physicians receive remuneration for digital EvoCare® treatment. As telemedicine specialist, EvoCare creates treatment methods for cross-sectoral application, to further promote digital healthcare with physicians and their patients through improved care.

February 1st, 2019

Press release: EvoCare® receives approval for digitized EvoCare therapy Link